FindTrial
Sign In

Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer

Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer - Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042333
Enrollment
300
Registered
2021-03-01
Start date
2021-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Sponsors

Saitama Medical University International Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients had received anti-PD-1/L1 antibody + chemotherapy (+bevacizumab) as the primary therapy, followed by secondary therapy with docetaxel/ramucirumab starting by August 31, 2020. 2. Patients aged 20 years or older

Exclusion criteria

Exclusion criteria: Patients judged by the principal investigator of each institution to be inappropriate for registration

Design outcomes

Primary

MeasureTime frame
Best response Last date of survival confirmation/date of death—

Countries

Japan

Contacts

Public ContactOu Yamaguchi

Saitama Medical University International Medical Center respiratory medicine

ouyamagu@saitama-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026